Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Editas
Editas
Editas brings on Sarepta CMO—for CEO swap, not the vacant CMO role
Fierce Biotech
Fri, 04/15/22 - 01:49 pm
Editas
Sarepta Therapeutics
Pharma CEOs
Gilmore O'Neill
JPM19: A biotech's M&A invitation, Editas' next CRISPR step and more from day 3
Biopharma Dive
Thu, 01/10/19 - 12:31 pm
Editas
CRISPR
GSK
Tesaro
Clovis Oncology
M&A
AbbVie
JPMHC 2019
[video+transcript] Gene-Editing Stocks Took Stutter Steps Forward in 2018
Motley Fool
Tue, 12/18/18 - 10:34 am
gene editing
Editas
Vertex Pharmaceuticals
CRISPR Therapeutics
Sangamo BioSciences
3 Great Acquisition Targets for Gilead Sciences -- and 1 Iffy Candidate
Motley Fool
Thu, 02/15/18 - 11:08 am
Gilead Sciences
M&A
Editas
Madrigal Pharmaceuticals
CRISPR Therapeutics
Galapagos
Who will pay for CRISPR?
Stat
Mon, 06/26/17 - 09:43 am
CRISPR
gene therapy
uniQure
Editas
Spark Therapeutics
Editas loses its lead in the biotech race to launch the first CRISPR/Cas9 human study
Endpoints
Tue, 05/16/17 - 11:35 am
Editas
CRISPR-Cas9
CRISPR Therapeutics
Intellia Therapeutics
Califf cautions against lowering FDA standards; Editas outlines $1B milestone package
Endpoints
Thu, 03/23/17 - 09:49 pm
Robert Califf
FDA
Editas
Allergan
CRISPR-Cas9
Allergan antes up $90M in a CRISPR/Cas9 collaboration with Editas on eye diseases
Endpoints
Tue, 03/14/17 - 09:42 am
Allergan
eye health
CRISPR-Cas9
Editas
Editas jumps into cystic fibrosis field with a $5M deal
Bizjournals.com
Mon, 05/16/16 - 11:53 am
Editas
cystic fibrosis
Cystic Fibrosis Foundation
Vertex Pharmaceuticals